Nabriva Therapeutics (NASDAQ:NBRV) Stock Rating Reaffirmed by Northland Securities

Nabriva Therapeutics (NASDAQ:NBRV)‘s stock had its “buy” rating reiterated by equities researchers at Northland Securities in a note issued to investors on Thursday, AnalystRatings.com reports. They presently have a $12.50 target price on the biotechnology company’s stock. Northland Securities’ price objective points to a potential upside of 410.20% from the stock’s previous close.

The analysts wrote, “We anticipate regulatory clearance of both oral and IV formulations, serving as a major near-term catalyst. We also anticipate clarity on the timing of the resubmission timing of CONTEPO in the weeks ahead. Take: NBRV reported 2Q19 results, w/ a net loss of ($21.8MM), comparing favorably to our forecast of ($23.7MM). EPS tracked ($0.30), vs. our forecast of ($0.33). R&D spending totaled $8.1MM, vs. our estimate of $10.3MM, w/ SG&A spend of $13.4MM, aligned w/ our expectations. The Co. ended the June 30th period w/ cash and equivalents of $73.9MM, which is expected to be sufficient to fund operations into 2Q20.””

A number of other analysts have also recently issued reports on NBRV. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective (down previously from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. BidaskClub cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 24th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Nabriva Therapeutics in a research report on Thursday, May 9th. ValuEngine raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Nabriva Therapeutics has an average rating of “Buy” and a consensus target price of $7.03.

Shares of Nabriva Therapeutics stock opened at $2.45 on Thursday. The stock has a fifty day simple moving average of $2.34. The company has a quick ratio of 5.55, a current ratio of 5.55 and a debt-to-equity ratio of 0.40. Nabriva Therapeutics has a 12 month low of $1.12 and a 12 month high of $3.27.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.04. The business had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.88 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. As a group, analysts predict that Nabriva Therapeutics will post -1.14 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Two Sigma Advisers LP purchased a new position in Nabriva Therapeutics during the fourth quarter worth about $37,000. Jane Street Group LLC purchased a new position in Nabriva Therapeutics during the fourth quarter worth about $29,000. FMR LLC lifted its position in Nabriva Therapeutics by 514.2% during the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock worth $2,690,000 after buying an additional 1,542,700 shares during the period. Fosun International Ltd purchased a new position in Nabriva Therapeutics during the first quarter worth about $1,593,000. Finally, Commonwealth Equity Services LLC lifted its position in Nabriva Therapeutics by 30.0% during the second quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock worth $157,000 after buying an additional 15,000 shares during the period. 3.01% of the stock is owned by institutional investors.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: Trade Deficit

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.